佐福替尼(Ziftomenib) - 药物靶点：MLL1 x menin_在研适应症：NPM1突变急性髓系白血病，伴有 11q23 异常的急性髓系白血病，复发性急性白血病_专利_临床

概要

基本信息

药物类型

小分子化药

别名

齐夫托美尼布、KO-381、KO-382

+ [4]

靶点

MLL1 x menin

作用方式

抑制剂

作用机制

MLL1抑制剂(lysine methyltransferase 2A inhibitors)、menin抑制剂(Menin蛋白抑制剂)

治疗领域

肿瘤血液及淋巴系统疾病免疫系统疾病+ [3]

在研适应症

NPM1突变急性髓系白血病伴有 11q23 异常的急性髓系白血病复发性急性白血病+ [8]

非在研适应症-

原研机构

Kura Oncology, Inc.

在研机构

Kura Oncology, Inc.

Kura Ltd.Sti.

非在研机构-

权益机构

Kyowa Kirin Co., Ltd.

The University of Texas MD Anderson Cancer Center

Kura Oncology, Inc.

最高研发阶段批准上市

首次获批日期

美国 (2025-11-13),

NPM1突变急性髓系白血病

最高研发阶段(中国)-

特殊审评优先审评 (美国)、突破性疗法 (美国)、孤儿药 (美国)、孤儿药 (欧盟)、快速通道 (美国)

登录后查看时间轴

结构/序列

分子式C33H42F3N9O2S2

InChIKeyBGGALFIXXQOTPY-NRFANRHFSA-N

CAS号2134675-36-6

关联

15

项与佐福替尼相关的临床试验

NCT07411586

/ Not yet recruiting临床1期IIT

Phase 1/1b Trial Of Olutasidenib And Ziftomenib For NPM1 And IDH1 Co-Mutated Acute Myeloid Leukemia

The goal of Phase 1 is to find the recommended dose of ziftomenib and olutasidenib in patients with relapsed/refractory AML that has a mutation in the NPM1 and IDH1 genes.
The goal of Phase 1b is to learn if the recommended dose of ziftomenib and olutasidenib found in Phase 1 can help to control the disease.
The safety and effects of this combination will also be studied in both parts.

开始日期2026-08-31

申办/合作机构

The University of Texas MD Anderson Cancer Center

NCT07355335

/ Not yet recruiting临床1期IIT

A Phase 1 Study of Menin-KMT2A Inhibitor Ziftomenib (KO-539) in Combination With Cereblon E3 Ligase Modulator Mezigdomide (CC-92480) in Adolescents and Adults With Relapsed or Refractory Acute Myeloid Leukemia (AML)

The purpose of this study is to evaluate the safety and tolerability of mezigdomide in combination with ziftomenib in adolescent and adult participants with either KMT2A-rearranged (KMT2A-r) or NPM1-mutant relapsed or refractory acute myeloid leukemia (AML).

开始日期2026-07-09

申办/合作机构

The Massachusetts General Hospital

[+2]

NCT06930352

/ Not yet recruiting临床2期IIT

Frontline Ziftomenib in NPM1-Mutated or KMT2A-Rearranged Acute Myeloid Leukemia in Patients Not Eligible for Intensive Induction or Other Therapy

This phase II trial tests how well ziftomenib works in treating patients with NPM1 mutated or KMT2A rearranged acute myeloid leukemia (AML) and are not eligible to receive standard therapy. AML is often due to genetic changes in the cancer cells, including mutations in the NPM1 gene and rearrangements involving the KMT2A gene. These mutations result in activation of the menin pathway. Menin is a type of protein in the body that helps to regulate some of the naturally occurring processes in the body, but can also be involved in some types of cancers. Ziftomenib blocks this menin pathway and may prevent the cancer cells from continuing to grow. Giving ziftomenib may kill more cancer cells in patients with NPM1 mutated or KMT2A rearranged AML that are not eligible to receive standard therapy.

开始日期2026-04-10

申办/合作机构

Ohio State University Comprehensive Cancer Center

[+1]

100 项与佐福替尼相关的临床结果

登录后查看更多信息

100 项与佐福替尼相关的转化医学

登录后查看更多信息

100 项与佐福替尼相关的专利（医药）

登录后查看更多信息

39

项与佐福替尼相关的文献（医药）

2026-03-01·CANCER

Two new options for NPM1-mutated relapsed, refractory acute myeloid leukemia: Researchers are looking into whether revumenib or ziftomenib can be combined with first-line standard-of-care treatment options.

作者: Lawrence, Leah

2026-02-27·AMERICAN JOURNAL OF HEMATOLOGY

The Care and Cure of the Leukemias in 2026.

Review

作者: Wierda, William ; Haddad, Fadi G ; Kadia, Tapan ; Kantarjian, Hagop ; Chifotides, Helen T ; Ravandi, Farhad ; Jabbour, Elias ; Freireich, Emil J ; Jain, Nitin ; Welch, Mary Alma

It is an exciting era in leukemia owing to the development of novel targeted therapies and advances in genomics, pathophysiology, prognostication, and monitoring (e.g., highly sensitive measurable residual disease assays). Currently, most leukemias are effectively treated with immunotherapies (highly effective monoclonal antibodies targeting CD19 [blinatumomab], or CD22 [inotuzumab ozogamicin]), BCR::ABL1 tyrosine kinase inhibitors (TKIs; e.g., dasatinib, ponatinib), Bruton TKIs (e.g., ibrutinib, acalabrutinib), BCL-2 inhibitors (venetoclax), IDH1/2 inhibitors (ivosidenib, olutasidenib, and enasidenib), FLT3 inhibitors (e.g., midostaurin, quizartinib, and gilteritinib), menin inhibitors (revumenib, ziftomenib), and chimeric antigen receptor T-cell therapies. These novel agents and their judicious use in combination strategies have transformed the treatment landscape across all leukemias, significantly increased survival and quality of life for patients, and attenuated the need for intensive chemotherapy and hematopoietic stem cell transplantation. Leukemia subtypes, such as Philadelphia-positive acute lymphoblastic leukemia (incurable before 2000) and chronic lymphocytic leukemia (previously considered incurable) with historically dire prognoses were recently transformed to favorable leukemias with 5- and 10-year survival rates of 80+% and 90+%, respectively. The BCR::ABL1 TKIs resulted in normal life expectancy in chronic myeloid leukemia. Notable advances have also been made in AML with targeted therapies, although some subsets (older/unfit patients for intensive chemotherapy, complex karyotype, TP53-mutated, KMT2A-rearranged, and treated secondary AML) still have unfavorable outcomes. Herein, we provide a high-level overview of prominent clinical developments across all leukemias. In contemporary times, harnessing the benefits of novel targeted therapies and the evolving treatment landscape bolster the optimistic view that most, if not all, leukemias are curable.

2025-12-05·Hematology-American Society of Hematology Education Program

The promise of menin inhibitors: from approval to triplet regimens

Review

作者: Thakur, Rahul K. ; Wang, Eunice S.

Abstract:

Pharmacologic targeting of the menin-KMT2A protein–protein interaction has emerged as a therapeutic breakthrough for acute leukemias harboring KMT2A rearrangements or NPM1 mutations. The first-in-class menin inhibitor (revumenib) achieved accelerated regulatory approval in November 2024 for monotherapy of relapsed/refractory KMT2A rearranged leukemia. Next-generation agents (ziftomenib, bleximenib, enzomenib, BMF-219) have displayed similar composite complete remission rates (20-35%) and overall response rates (45-65%) in heavily pretreated KMT2Ar and NPM1m acute myeloid leukemia (AML) with measurable residual disease (MRD) negativity and prolonged overall survival (5–7 months). While all menin inhibitors result in on-target blast differentiation with clinical sequelae (“differentiation syndrome”) in 10% to 20% of patients, not all menin inhibitors are the same, with differing safety, toxicity (heartrate corrected QT interval (QTc) prolongation, cytopenias), and pharmacokinetic profiles. Acquired mutations in the menin gene described in 39% of post-revumenib relapses have not been identified following other inhibitors (ziftomenib, bleximenib), prompting new questions about resistance mechanisms. These promising results swiftly led to the launch of multiple trials of menin inhibitors combined with intensive (cytarabine and anthracycline) and nonintensive (venetoclax and hypomethylating) chemotherapy backbones. To date, these triplets have yielded high response rates (ie, ≥80% in de novo, 50-70% in relapsed) with most patients achieving MRD negativity and prolonged one-year survival. Ongoing/pending phase 3 trials will clarify whether menin blockade should be incorporated into frontline and maintenance regimens for all patients with KMT2A rearranged or NPM1 mutant disease. In the current era, menin inhibition remains a key pillar of the success of precision medicine for AML therapy.

280

项与佐福替尼相关的新闻（医药）

2026-03-12

·化学经纬

2025年FDA批准的16款含有卤素原子的药物分子

在2025年FDA批准的46款新药中，有30款是小分子药物。其中，竟有16款（超过半数！）都含有卤素原子，再次印证了卤素在新药研发中的核心地位。今天，我们就来盘一盘这16颗“卤”力全开的明日之星。卤素的“超能力”一览 1）氟 (F)：最常见的卤素明星。引入氟原子或含氟基团（如CF3）可显著提升药物分子的效力、膜通透性和代谢稳定性，同时降低相邻官能团的pKa值，并“锁定”优势构象。2025年批准的16款含卤药物中，多数都含有氟。 2）氯 (Cl)：卤键的“主力军”。氯原子不仅能像氟一样优化分子性质，还能形成关键的“卤键”——一种可增强与靶点结合力、选择性和效力的非共价相互作用。它是仅次于氟的第二常用卤素。 3）溴 (Br) & 碘 (I)：“特型演员”。虽然应用不如氟、氯广泛，但溴和碘凭借其特殊的原子半径，能在特定情况下更好地填充蛋白口袋，形成卤键。碘试剂还在蛋白质后期修饰、前药（如PROTACs）构建及影像诊断（PET/SPECT）中展现出独特潜力。下面梳理了这16款在2025年获得FDA批准的、含卤素的小分子药物核心信息。 Journavy (Suzetrigine/口服)，批准日期 2025/1/30，适应症为中重度急性疼痛。 Gomekli (Mirdametinib/口服)，批准日期 2025/2/11，适应症为1型神经纤维瘤病。 Avmapki Fakzynja Co-Pack (Avutometinib and Defactinib/口服)，批准日期 2025/5/8，适应症为 KRAS突变的复发性低级别浆液性卵巢癌。 Ibtrozi (Taletrectinib/口服)，批准日期 2025/6/11，适应症为局部晚期或转移性ROS1阳性非小细胞肺癌。 Zegfrovy (Sunvozertinib/口服)，批准日期 2025/7/2，适应症为局部晚期或转移性非小细胞肺癌 (EGFR 20号外显子插入突变)。 Ekterly (Sebetralstat/口服)，批准日期 2025/7/3，适应症为遗传性血管性水肿的急性发作。 Wayrilz (Rilzabrutinib/口服)，批准日期 2025/8/29，适应症为持续性或慢性免疫性血小板减少症。 Inluriya (Imlunestrant/口服)，批准日期 2025/9/25，适应症为 ER+/HER2-、ESR1突变的晚期或转移性乳腺癌。 Palsonify (Paltusotine/口服)，批准日期 2025/9/25，适应症为肢端肥大症。 Rhapsido (Remibrutinib/口服)，批准日期2025/9/30，适应症为慢性自发性荨麻疹。 Jascayd (Nerandomilast/口服)，批准日期 2025/10/7，适应症为特发性肺纤维化。 Lynkuet (Elinzanetant/口服)，批准日期 2025/10/24，适应症为因更年期引起的中重度血管舒缩症状。 Komzifti (Ziftomenib/口服)，批准日期 2025/11/13，适应症为复发或难治性NPM1突变的急性髓系白血病。 Hyrnuo (Sevabertinib/口服)，批准日期 2025/11/19，适应症为局部晚期或转移性非鳞状非小细胞肺癌 (具有激活的HER2酪氨酸激酶域突变)。 Nuzolvence (Zolifodacin/口服)，批准日期2025/12/12，适应症为由淋病奈瑟菌引起的单纯性泌尿生殖道淋病。 Nereus (Tradipitant/口服)，批准日期 2025/12/30，适应症为运动引起的呕吐。 2025年FDA批准的药物名单再次强有力地证明了卤素，特别是氟和氯，在优化药物分子、克服开发瓶颈方面的不可替代性。从提升效力、改善药代动力学性质，到形成关键的卤键相互作用，这些小小的原子在新药设计中扮演着“四两拨千斤”的角色。参考文献：J. Med. Chem. 2026, 69, 3649−3655

2026-03-11

·百度百家

癌症治疗的“范式革命”：从“广谱轰炸”到“精准制导”，这些新疗法正在改写规则

当“抗癌神药”K药年销售额突破300亿美元，你可能以为癌症治疗已经走到尽头。但实际上，一场更深远的变革正在暗流涌动。从ADC（抗体偶联药物）到放射性配体疗法，从双特异性抗体到体内CAR-T，肿瘤治疗正以前所未有的速度向“复杂性”与“精准性” 两个极致狂奔。MD Anderson癌症中心权威专家深度解析：未来的抗癌武器库，究竟长什么样？一、核心转变：肿瘤抗原成为“导航信标”，四大武器平台成型过去十年，癌症治疗的最大进步，是学会了如何“精准制导”。MD Anderson癌症中心治疗发现部门副总裁Tim Heffernan博士指出，肿瘤特异性抗原正被用作分子“信标”，锚定四大类核心疗法： ADC（抗体偶联药物）：像“生物导弹”，将细胞毒性载荷精准投送至肿瘤细胞。细胞疗法（CAR-T/CAR-NK）：改造免疫细胞，使其能精准识别并杀伤肿瘤。免疫细胞衔接器：将T细胞或NK细胞“拉”到肿瘤细胞身边，激活局部免疫攻击。放射性配体疗法：将高能、短程辐射精准递送至肿瘤内部，实现“内部放疗”。靶点版图扩张：随着蛋白质工程技术成熟，高价值靶点已从传统的CD19、HER2、TROP2，扩展到BCMA、B7-H3、DLL3、PSMA、STEAP1等新星。这意味着更多类型的肿瘤将拥有专属“导航信标”。二、攻克肿瘤微环境：免疫激活的“空间控制术” 肿瘤微环境是癌细胞藏身的“免疫黑洞”。新一代疗法正通过巧妙设计，实现免疫激活的空间精准控制：新型免疫细胞衔接器：基于CD3、4-1BB、CD16a等设计的衔接器，能将免疫激活严格限制在肿瘤内部，避免全身性炎症风暴。武装化双特异性抗体：以PD-L1×VEGF双抗为代表，在一个分子上整合了解除免疫抑制（抗PD-L1）+ 阻断肿瘤血管生成（抗VEGF）双重功能，实现“1+1>2”的协同效应。工程化细胞因子：如IL-12等强效免疫刺激因子，通过靶向递送策略，在发挥药效的同时避免全身毒性，解决了困扰行业数十年的难题。三、液体肿瘤的三大突破：TCE、Menin抑制剂与克服耐药血液肿瘤领域，同样迎来里程碑式进展： 1. T细胞衔接器崛起：CD20×CD3、BCMA×CD3、GPRC5D×CD3双抗已获批上市，在多发性骨髓瘤和B细胞淋巴瘤中展现出媲美CAR-T的疗效，且无需复杂定制。 2. Menin抑制剂改写白血病治疗：Revumenib、ziftomenib等Menin抑制剂获批用于治疗MLL重排或NPM1突变的急性白血病，这是针对特定分子亚型的精准疗法典范。 3. 克服BTK抑制剂耐药：非共价BTK抑制剂pirtobrutinib的获批，为对一代BTK抑制剂耐药的慢性淋巴细胞白血病患者提供了全新的治疗选择。四、引爆行业热情的六大前沿阵地哪些领域正在吸引最多投资与关注？Heffernan博士指出了六大热点：五、值得关注的潜力候选药物与概念 PD-L1×VEGF双抗：以依沃西单抗为代表的数据已成为行业标杆，有望重塑免疫联合治疗格局。KRAS靶向药：继两款抑制剂获批后，pan-RAS抑制剂及新一代选择性抑制剂（如RMC-6236在胰腺癌中的活性）正带来更广泛的临床突破。新型ADC靶点：B7-H3、CLDN18.2、Nectin-4等成为继HER2/TROP2后的新热点，双特异性ADC和新型载荷（超越拓扑异构酶抑制剂）备受期待。体内CAR-T：通过脂质纳米颗粒或病毒载体，在患者体内直接生成CAR-T细胞，有望将天价疗法降至普通患者可及。六、最大挑战：肿瘤生物学复杂性与治疗窗口尽管进展惊人，但Heffernan博士也直言不讳地指出了三大根本挑战： 1. 生物学复杂性：肿瘤是动态演化系统，存在异质性、通路冗余和适应性耐药。空间生物学与单细胞测序正在帮助科学家看清“敌人”的全貌，指导更智慧的联合用药策略。 2. 毒性困境：无论何种新疗法，靶点正常功能、脱靶效应或系统性免疫激活都可能导致治疗窗口狭窄，限制剂量强度与联合用药的可能性。 3. 转化鸿沟：从临床前模型到患者的“跳跃”，充满不确定性。七、结语：新药研发的“集成化”时代正在到来 MD Anderson的独特之处在于，它将发现科学、转化研究与临床开发整合为同一台“引擎”。在这里，新兴临床数据能实时指导投资组合决策，科学概念能以最快速度进入临床测试。 Heffernan博士的洞见清晰地表明：未来的癌症治疗，将是多种复杂模态的协同作战。ADC负责精准杀伤，双抗负责免疫唤醒，RLT负责局部清除，AI负责全程加速。这场从“广谱轰炸”到“精准制导”的范式革命，才刚刚拉开序幕。

免疫疗法细胞疗法抗体药物偶联物

2026-03-05

·EndPoints

Kura says its menin inhibitor is preferred treatment for a 'handful' of payers

Both Kura Oncology and Syndax Pharmaceuticals have touted strong launches for their rival menin inhibitors in acute myeloid leukemia. But Kura says it may have a “competitive advantage” when it comes to certain insurance plans. On Thursday’s fourth-quarter earnings call, Kura commercial chief Brian Powl said “certain Blue plans” are recommending that some adults try Kura and Kyowa Kirin’s drug Komzifti before receiving coverage for Syndax’s Revuforj. Powl said a “handful” of plans have adopted the requirements, called step edits, but declined to provide a specific number. “It’s encouraging for us as we look to become the class leader here,” he added. Komzifti was approved in November for relapsed or refractory AML patients with NPM1 mutations. The approval came weeks after Syndax’s Revuforj won a label expansion in the same patient population. Revuforj has been on the market for more than a year to treat patients with KMT2A rearrangements, a less common genetic alteration that’s been linked to a more aggressive form of the disease. While Syndax has the advantage of being first to market, Kura CEO Troy Wilson told investors on Thursday that “leadership in relapsed and refractory NPM1-mutant AML will be determined by preference.” He touted Komzifti’s safety profile and once-daily dosing. Komzifti has a black box warning for an acute inflammatory reaction called differentiation syndrome. Revuforj is taken twice daily and has a black box warning for three conditions: differentiation syndrome, and two heart conditions called QTc prolongation and Torsades de Pointes. But Revuforj has a broader label, approved for KMT2A patients and children. Both companies are now racing to move into the first-line setting. Syndax CEO Michael Metzger said during the company’s earnings call last month that its launch in NPM1 patients was “off to an excellent start,” building on a “solid foundation” established through its launch in KMT2A patients. “We are confident we will win in NPM1 with a best-in-class product profile, including the broadest label and unmatched efficacy data, together with strong customer relationships and excellent market access,” Metzger said. Syndax was not immediately available for comment on Thursday.

上市批准

100 项与佐福替尼相关的药物交易

登录后查看更多信息

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
NPM1突变急性髓系白血病	美国	Kura Ltd.Sti.	2025-11-13
NPM1突变急性髓系白血病	美国	Kura Oncology, Inc.	2025-11-13

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
伴有 11q23 异常的急性髓系白血病	临床2期	美国	Kura Oncology, Inc.	2026-04-10
复发性急性白血病	临床2期	美国	Kura Oncology, Inc.	2020-06-17
复发性急性白血病	临床2期	比利时	Kura Oncology, Inc.	2020-06-17
复发性急性白血病	临床2期	加拿大	Kura Oncology, Inc.	2020-06-17
复发性急性白血病	临床2期	法国	Kura Oncology, Inc.	2020-06-17
复发性急性白血病	临床2期	德国	Kura Oncology, Inc.	2020-06-17
复发性急性白血病	临床2期	意大利	Kura Oncology, Inc.	2020-06-17
复发性急性白血病	临床2期	波兰	Kura Oncology, Inc.	2020-06-17
复发性急性白血病	临床2期	西班牙	Kura Oncology, Inc.	2020-06-17
复发性急性白血病	临床2期	英国	Kura Oncology, Inc.	2020-06-17

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05735184 (KOMET-007, ASH2025)	临床1期	NPM1突变急性髓系白血病 NPM1-mutation	39	AzacitidineVenetoclax 600 mg + AzacitidineVenetoclax + AzacitidineVenetoclaxe (Newly diagnosed NPM1-m AML)	觸鏇製糧憲廠淵淵糧憲(積廠鬱繭醖糧襯襯觸艱) = 襯廠夢遞餘艱網糧餘艱憲築憲積鑰簾遞鹹觸觸 (範糧鏇壓艱鹹壓糧衊構 ) 更多	积极	2025-12-06
NCT04067336 (KOMET-001, Pubmed \| J Clin Oncol)	临床1/2期	NPM1突变急性髓系白血病 NPM1-mutated	92	Ziftomenib 600 mg	願艱鏇衊壓憲窪鏇築膚(醖齋鏇廠衊繭構構窪廠) = 襯廠糧構願餘鬱製顧鹽窪築簾齋簾網鏇夢鑰範 (鏇繭網膚範鹹餘壓築餘, 14 ~ 32) 更多	积极	2025-11-01
NCT04067336 (KOMET-001, ASCO2025) 人工标引	临床1/2期	NPM1突变急性髓系白血病 NPM1 Mutation	112	Ziftomenib 600 mg QDZiftomenib 600 mg QD (Phase 1b/2)	鹽鹹襯鑰艱願襯鑰觸範(遞鏇鹽廠鹽餘鑰鹽積積) = 鬱艱築構蓋鹹選淵廠餘築衊襯繭憲齋繭餘醖糧 (淵鬱鏇選廠窪淵築製鬱, 17 ~ 34) 更多	积极	2025-05-30
NCT04067336 (KOMET-001, ASCO2025) 人工标引	临床1/2期	NPM1突变急性髓系白血病 NPM1 Mutation	112	Ziftomenib 600 mg QDZiftomenib 600 mg QD (Phase 2)	鹽鹹襯鑰艱願襯鑰觸範(遞鏇鹽廠鹽餘鑰鹽積積) = 餘廠蓋範廠簾鬱觸壓鏇築衊襯繭憲齋繭餘醖糧 (淵鬱鏇選廠窪淵築製鬱, 15 ~ 33)	积极	2025-05-30
NCT04067336 (KOMET-001, EHA2025)	临床1/2期	NPM1突变急性髓系白血病 NPM1-mutant	112	Ziftomenib 600 mg QD	鏇築艱衊鬱壓網淵醖構(網構淵顧繭鹽鹹艱鹹製) = 醖艱憲顧構蓋窪憲蓋鏇簾顧鹹獵築鑰衊範艱廠 (簾憲憲鹽顧淵鑰鹽蓋醖, 17 ~ 34) 更多	积极	2025-05-22
NCT05735184 (KOMET-007, EHA2025)	临床1期	伴有 11q23 异常的急性髓系白血病 \| NPM1突变急性髓系白血病 NPM1-m \| KMT2A-r	51	Ziftomenib 600 mg QD + 7+3 induction	艱簾遞繭憲積淵網選襯(襯餘襯繭鏇廠鏇鬱齋選) = febrile neutropenia (47%), decreased platelet count (31%), anemia (22%), decreased neutrophil count (20%), decreased white blood cell count (16%) 鑰願鹽構鹹築淵夢繭觸 (憲齋襯壓淵獵製齋壓艱 ) 更多	积极	2025-05-14
NCT04067336 (KOMET-001, Company_Website) 人工标引	临床1/2期	急性髓性白血病 NPM1 Mutation	-	Ziftomenib	鬱餘獵齋簾膚鹽廠淵衊(築範獵鹹夢構獵築網窪) = The KOMET-001 trial achieved its primary endpoint of CR plus CR with partial hematological recovery (CRh) and the primary endpoint was statistically significant. 鹽網鹽繭襯構鑰糧糧鑰 (夢觸憲餘襯壓顧獵積壓 ) 达到更多	积极	2025-02-07
KOMET-007 (GlobeNewswire) 人工标引	临床1期	NPM1突变急性髓系白血病 \| KMT2A易位的急性白血病一线 NPM1 Mutation \| KMT2A Rearrangement	54	ziftomenib +venetoclax/azacitidine	範淵構鑰淵獵膚醖繭範(選鏇鹹廠觸餘壓艱觸醖) = 艱觸淵醖選願夢製製餘範網顧夢選選網願遞遞 (願積積衊繭蓋糧鹹壓餘 ) 更多	积极	2024-12-09
KOMET-007 (GlobeNewswire) 人工标引	临床1期		54	Ziftomenib+cytarabinecytarabine/daunorubicindaunorubicin	範淵構鑰淵獵膚醖繭範(選鏇鹹廠觸餘壓艱觸醖) = 衊獵願蓋簾遞醖齋願淵範網顧夢選選網願遞遞 (願積積衊繭蓋糧鹹壓餘 ) 更多	积极	2024-12-09
ASH2024	N/A	-	-	Ziftomenib 200 mg	製鏇餘窪顧膚鬱獵顧餘(壓襯鑰網醖衊顧壓鬱觸) = 鑰蓋齋遞鹹觸鹽網壓築淵顧願鹽鬱膚糧築獵夢 (製簾獵艱遞醖齋鹽憲壓 ) 更多	-	2024-12-08
ASH2024	N/A	-	-	Ziftomenib 400 mg	製鏇餘窪顧膚鬱獵顧餘(壓襯鑰網醖衊顧壓鬱觸) = 窪廠觸夢範顧齋積膚窪淵顧願鹽鬱膚糧築獵夢 (製簾獵艱遞醖齋鹽憲壓 ) 更多	-	2024-12-08
ASH2024	N/A	-	-	Ziftomenib 200 mg	願構膚積窪鹽範艱選廠(積膚積鑰願鹽艱艱醖襯) = 網簾餘夢繭齋獵鹽鹽鑰膚餘觸遞製醖膚選餘築 (膚醖醖艱範淵壓壓遞夢 )	-	2024-12-07
ASH2024	N/A	-	-	Ziftomenib 400 mg	願構膚積窪鹽範艱選廠(積膚積鑰願鹽艱艱醖襯) = 醖齋範築衊窪窪製憲積膚餘觸遞製醖膚選餘築 (膚醖醖艱範淵壓壓遞夢 )	-	2024-12-07
NCT04067336 (KOMET-001, Pubmed \| Lancet Oncol) 人工标引	临床1/2期	急性髓性白血病 NPM1 Mutation \| KMT2A Rearrangement	83	Ziftomenib 50-1000 mg	壓簾艱窪醖願簾願鬱願(簾窪製艱鬱鹹範築簾選) = the most common grade 3 or worse treatment-emergent adverse events were anaemia (20 [24%]), febrile neutropenia (18 [22%]), pneumonia (16 [19%]), differentiation syndrome (12 [15%]), thrombocytopenia (11 [13%]), and sepsis (ten [12%]). 憲構鏇蓋糧範築積鹽鏇 (壓鹹網鏇願鑰糧夢蓋廠 ) 更多	积极	2024-10-01